These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 16394805)
1. Management of multiple intrahepatic recurrences after radiofrequency ablation of hepatocellular carcinoma with rhenium-188-HDD-lipiodol. Kumar A; Bal C; Srivastava DN; Thulkar SP; Sharma S; Acharya SK; Duttagupta S Eur J Gastroenterol Hepatol; 2006 Feb; 18(2):219-23. PubMed ID: 16394805 [TBL] [Abstract][Full Text] [Related]
2. Management of postsurgical recurrence of hepatocellular carcinoma with rhenium 188-HDD labeled iodized oil. Kumar A; Srivastava DN; Bal C J Vasc Interv Radiol; 2006 Jan; 17(1):157-61. PubMed ID: 16415146 [TBL] [Abstract][Full Text] [Related]
3. Biologic dosimetry of 188Re-HDD/lipiodol versus 131I-lipiodol therapy in patients with hepatocellular carcinoma. De Ruyck K; Lambert B; Bacher K; Gemmel F; De Vos F; Vral A; de Ridder L; Dierckx RA; Thierens H J Nucl Med; 2004 Apr; 45(4):612-8. PubMed ID: 15073257 [TBL] [Abstract][Full Text] [Related]
4. Inoperable hepatocellular carcinoma: transarterial 188Re HDD-labeled iodized oil for treatment--prospective multicenter clinical trial. Kumar A; Srivastava DN; Chau TT; Long HD; Bal C; Chandra P; Chien le T; Hoa NV; Thulkar S; Sharma S; Tam le H; Xuan TQ; Canh NX; Pant GS; Bandopadhyaya GP Radiology; 2007 May; 243(2):509-19. PubMed ID: 17456873 [TBL] [Abstract][Full Text] [Related]
5. Preliminary results of transarterial rhenium-188 HDD lipiodol in the treatment of inoperable primary hepatocellular carcinoma. Sundram F; Chau TC; Onkhuudai P; Bernal P; Padhy AK Eur J Nucl Med Mol Imaging; 2004 Feb; 31(2):250-7. PubMed ID: 15129708 [TBL] [Abstract][Full Text] [Related]
6. Preliminary experience in radionuclide therapy of hepatocellular carcinoma using hepatic intra-arterial radio-conjugates. Keng GH; Sundram FX; Yu SW; Somanesan S; Premaraj J; Oon CJ; Kwok R; Htoo MM Ann Acad Med Singap; 2002 May; 31(3):382-6. PubMed ID: 12061301 [TBL] [Abstract][Full Text] [Related]
7. (188)Re-HDD/lipiodol therapy for hepatocellular carcinoma: an activity escalation study. Lambert B; Bacher K; Defreyne L; Van Vlierberghe H; Jeong JM; Wang RF; van Meerbeeck J; Smeets P; Troisi R; Thierens H; De Vos F; Van de Wiele C Eur J Nucl Med Mol Imaging; 2006 Mar; 33(3):344-52. PubMed ID: 16333675 [TBL] [Abstract][Full Text] [Related]
8. Use of the Oak Ridge National Laboratory tungsten-188/rhenium-188 generator for preparation of the rhenium-188 HDD/lipiodol complex for trans-arterial liver cancer therapy. Jeong JM; Knapp FF Semin Nucl Med; 2008 Mar; 38(2):S19-29. PubMed ID: 18243839 [TBL] [Abstract][Full Text] [Related]
9. Empirical 188Re-HDD/lipiodol intra-arterial therapy based on tumor volume, in patients with solitary inoperable hepatocellular carcinoma. Shinto AS; Karuppusamy KK; Kurup RER; Pandiyan A; Jayaraj AV Nucl Med Commun; 2021 Jan; 42(1):43-50. PubMed ID: 32956248 [TBL] [Abstract][Full Text] [Related]
10. Ablation of recurrent primary liver cancer using 131I-lipiodol. Novell R; Hilson A; Hobbs K Postgrad Med J; 1991 Apr; 67(786):393-5. PubMed ID: 1648718 [TBL] [Abstract][Full Text] [Related]
11. 188Re-HDD/lipiodol therapy for hepatocellular carcinoma: a phase I clinical trial. Lambert B; Bacher K; Defreyne L; Gemmel F; Van Vlierberghe H; Jeong JM; Dierckx RA; Van de Wiele C; Thierens H; De Vos F J Nucl Med; 2005 Jan; 46(1):60-6. PubMed ID: 15632035 [TBL] [Abstract][Full Text] [Related]
12. International Atomic Energy Agency-sponsored multination study of intra-arterial rhenium-188-labeled lipiodol in the treatment of inoperable hepatocellular carcinoma: results with special emphasis on prognostic value of dosimetric study. Bernal P; Raoul JL; Stare J; Sereegotov E; Sundram FX; Kumar A; Jeong JM; Pusuwan P; Divgi C; Zanzonico P; Vidmar G; Buscombe J; Chau TT; Saw MM; Chen S; Ogbac R; Dondi M; Padhy AK Semin Nucl Med; 2008 Mar; 38(2):S40-5. PubMed ID: 18243842 [TBL] [Abstract][Full Text] [Related]
13. Re-188 lipiodol in hepatocellular carcinoma with portal vein thrombosis: a pilot study using novel chelating agent N-DEDC and its comparison with (A)HDD. Datta Gupta SS; Shamim SA; Gamanagatti S; Gupta P; Khan MA; Mallia MB; Chirayil V; Dash A; Bal C Nucl Med Commun; 2024 Jun; 45(6):510-518. PubMed ID: 38632971 [TBL] [Abstract][Full Text] [Related]
14. Development of 4-hexadecyl-4,7-diaza-1,10-decanedithiol (HDD) kit for the preparation of the liver cancer therapeutic agent Re-188-HDD/lipiodol. Banka VK; Moon SH; Jeong JM; Seelam SR; Lee YS; Kim YJ; Lee DS; Chung JK Nucl Med Biol; 2015 Mar; 42(3):317-22. PubMed ID: 25537725 [TBL] [Abstract][Full Text] [Related]
15. 188Re-HDD/lipiodol for treatment of hepatocellular carcinoma: a feasibility study in patients with advanced cirrhosis. Lambert B; Bacher K; De Keukeleire K; Smeets P; Colle I; Jeong JM; Thierens H; Troisi R; De Vos F; Van de Wiele C J Nucl Med; 2005 Aug; 46(8):1326-32. PubMed ID: 16085590 [TBL] [Abstract][Full Text] [Related]
16. Lipiodol solution of 188Re-HDD as a new therapeutic agent for transhepatic arterial embolization in liver cancer: preclinical study in a rabbit liver cancer model. Paeng JC; Jeong JM; Yoon CJ; Lee YS; Suh YG; Chung JW; Park JH; Chung JK; Son M; Lee MC J Nucl Med; 2003 Dec; 44(12):2033-8. PubMed ID: 14660730 [TBL] [Abstract][Full Text] [Related]
17. Evaluating the potential of (188)Re-ECD/lipiodol as a therapeutic radiopharmaceutical by intratumoral injection for hepatoma treatment. Luo TY; Shih YH; Chen CY; Tang IC; Wu YL; Kung HC; Lin WJ; Lin XZ Cancer Biother Radiopharm; 2009 Oct; 24(5):535-41. PubMed ID: 19877883 [TBL] [Abstract][Full Text] [Related]
18. Synthesis and application of 188Re-MN-16ET/Lipiodol in a hepatocellular carcinoma animal model. Tang IC; Luo TY; Liu SW; Chan SH; Kung HC; Peng CL; Lin WY; Chang Y; Lin WJ Nucl Med Biol; 2011 Oct; 38(7):1043-52. PubMed ID: 21831647 [TBL] [Abstract][Full Text] [Related]